Protagonist Therapeutics, Inc.
PTGX
Classifica tra le azioni
#2241
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Prezzo delle azioni
$138.89
Capitalizzazione di mercato
$8.99B
Variazione (1 giorno)
3.31%
Variazione (1 anno)
81.03%
Paese
US
Scambia Protagonist Therapeutics, Inc. (PTGX)
Categoria
Healthcare
Utile per Protagonist Therapeutics, Inc. (PTGX)
Utile nel Jun 2026 TTM: $84.34M
Secondo gli ultimi rapporti finanziari di Protagonist Therapeutics, Inc., gli utili attuali della società sono $84.34M. Nel 2023, la società ha registrato un utile di $-78.96M, un aumento rispetto a agli utili del 2022, che erano di $-127.39M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Protagonist Therapeutics, Inc. dal 2014 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $84.34M | -69.82% |
| 2024 | $279.41M | -453.88% |
| 2023 | $-78.96M | -38.02% |
| 2022 | $-127.39M | 1.47% |
| 2021 | $-125.55M | 93.62% |
| 2020 | $-64.85M | -16.74% |
| 2019 | $-77.88M | 96.05% |
| 2018 | $-39.72M | 7.48% |
| 2017 | $-36.96M | -0.59% |
| 2016 | $-37.18M | 150.22% |
| 2015 | $-14.86M | 34.19% |
| 2014 | $-11.07M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | 6,154.48% |
US
|
|
| $-3.09B | -3,760.27% |
US
|
|
| $-4.02B | -4,862.02% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 2,212.90% |
NL
|
